Trials / Completed
CompletedNCT02273700
Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention
Evaluation of Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention in Patients With Atrial Fibrillation
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nīmes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this pilot study is to investigate the protein / peptide plasma profiles before and after treatment with a direct anti-Xa (activated Factor 10) in patients with non-valvular atrial fibrillation to better understand the mechanisms of action of these molecules and perform exploratory analyses concerning proteins whose concentrations change after starting treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban | Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care. |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2014-10-24
- Last updated
- 2016-08-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02273700. Inclusion in this directory is not an endorsement.